Drug Discovery World
JULY 11, 2022
Biotechnology company Awakn Life Sciences has received funding from Innovate UK to help it advance its ketamine-assisted therapy programme to market in the UK and US. . Awakn Life Sciences has developed a ketamine-assisted therapy programme for treating alcohol use disorder (AUD). The company plans to work with clinical research organisation (CRO) Veristat to deliver its programmes. .
Drug Discovery Today
JULY 18, 2022
Imagen Therapeutics, a global provider of services to the pharmaceutical cancer drug development industry, is celebrating recent success and preparing for rapid growth following the opening of its headquarters at Sci-Tech Daresbury.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Antidote
JULY 13, 2022
Before a potential new therapy can be administered to patients, it must go through several clinical trial phases designed to test the drug or device for safety and effectiveness. For many new treatments, it will take approximately ten years for the therapy to progress from initial discovery to being approved. Clinical trials alone take six to seven years on average to complete.
Drug Channels
JULY 28, 2022
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Click here to see the original post from May 2022. Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. This year’s review includes 10 companies: Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda, and UCB.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
JULY 1, 2022
Annual Drug Patent Expirations for AIRDUO+RESPICLICK Airduo Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are sixteen…. The post New patent for Teva Pharm drug AIRDUO RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Advarra
JULY 26, 2022
Cannabis use has become widespread. As such, we are seeing an uptick in research examining the therapeutic effects of cannabis and its constituents. Currently, cannabis use is legal across many states in the U.S., with 37 states approving medicinal use and 18 approving recreationally. However, it’s not legal federally and is considered a Schedule I drug by the U.S.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Discovery Today
JULY 1, 2022
Barclays has selected Discovery Park in Kent as the home for its latest Eagle Lab which will open later this year. The lab will help facilitate collaboration between the Life Sciences and Technology sectors, with the aim of driving development of a community base focused on clean energy, agri-tech and addressing future challenges in healthcare.
Antidote
JULY 25, 2022
Atopic dermatitis is a type of eczema, a skin condition caused by an overactive immune system that can lead to redness, blotchiness, and itching, typically on the face, arms, and legs. Atopic dermatitis is the most common type of eczema , impacting more than 9.6 million children and 16.5 million adults worldwide.
Drug Channels
JULY 29, 2022
This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Note that the forecasts below did not account for policy changes that could further reduce pharmaceuticals' share of U.S. healthcare spending. Click here to see the original post from April 2022.
Drug Patent Watch
JULY 1, 2022
Annual Drug Patent Expirations for LICART Licart is a drug marketed by Ibsa Inst Bio and is included in one NDA. The generic ingredient in LICART is diclofenac epolamine. Additional…. The post New patent for Ibsa Inst drug LICART appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Advarra
JULY 5, 2022
Individuals invest a great deal to participate in clinical research, undertaking risks and burdens, while giving of their time and energies to advance scientific knowledge and the public good. Empirical research into participant views and experiences has consistently shown participants desire to learn the results of research to which they’ve contributed.
Drug Discovery World
JULY 29, 2022
From immunity to metabolism to mental health, it seems like the gut microbiome has been linked to every aspect of human health and disease. But with hundreds of bacterial species populating our gastrointestinal tract, it’s a daunting task to pinpoint which molecules made by which bacteria affect which biological processes—and how they do so. “Microbiome studies need to move from making associations to determining function and causation,” said Ramnik Xavier, the Kurt J.
Drug Discovery Today
JULY 7, 2022
Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapiesAgreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercializationAccess to dbDNA patent rights enables Pfizer’s rapid production of DNA template as starting materials for mRNA-based vaccines and other therapeutics
Antidote
JULY 22, 2022
Skin cancer is more common than any other type of cancer, and melanoma causes a large majority of skin cancer-related deaths. While awareness surrounding melanoma and the importance of sun protection has risen in recent years, CDC research shows that melanoma rates have still doubled over the last three decades.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Channels
JULY 25, 2022
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Click here to see the original post from April 2022. The highly-consolidated PBM market notched another year of increased concentration. Consider Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share, shown in the chart below.
Drug Patent Watch
JULY 1, 2022
Annual Drug Patent Expirations for ARMONAIR+RESPICLICK Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are thirteen…. The post New patent for Teva Pharm drug ARMONAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Olympian Clinical Research
JULY 12, 2022
Depression is an illness that affects nearly 280 million people worldwide. There are several types of depression, each with its own set of symptoms and recommended treatment methods. Therefore, overcoming depression requires understanding the type of depression you may be facing and getting the proper help. 1. Major Depressive Disorder. Major depressive disorder ( MDD ), also known as clinical depression, is characterized by a persistent feeling of sadness or emptiness lasting for at least two w
Drug Discovery World
JULY 28, 2022
The world of work has changed since Covid for employees and employers in biotech. Singular Talent is carrying out a research survey to determine what the biotech landscape will look like in future years. It would like your views on attitudes and approaches in working in the biotech sector. Early predictions are that work may transition to be centred on social and learning & development hubs.
Drug Discovery Today
JULY 29, 2022
Geneva-based event pledges five Swiss francs per visitor to support new drug development project
Antidote
JULY 21, 2022
Not being able to recall an actor’s name or where you set down your keys is not always a major concern, but if these incidents are happening often — or causing you to forget life’s more important details — it’s understandable to worry.
Drug Channels
JULY 15, 2022
Today’s guest post comes from Carolyn Zele, Senior Manager of Solution Enablement at MMIT. Carolyn explains the advantages of alternative payment models (APM) for measuring and rewarding value and outcomes in our healthcare system. For more on how APMs measure value, click here to learn about MMIT’s Pulse Analytics Solution. Read on for Carolyn’s insights.
Drug Patent Watch
JULY 1, 2022
Annual Drug Patent Expirations for WEGOVY Wegovy is a drug marketed by Novo and is included in one NDA. It is available from two suppliers. There are four patents protecting…. The post New patent for NOVO drug WEGOVY appeared first on DrugPatentWatch - Make Better Decisions.
Eye on FDA
JULY 5, 2022
We are at mid-year, a good time to check in and see how we are doing on a number of fronts – including where we are with new drug approvals. Over the years, Congress has acted to enhance the ability to bring more new treatments from test tube to medicine chest more quickly. Most notably in 2012 the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law, bring to bear among other things, breakthrough therapy designation.
Drug Discovery World
JULY 28, 2022
Researchers at the Francis Crick Institute in the UK, have shown that a specific area of the SARS-CoV-2 spike protein is a promising target for a pan-coronavirus vaccine that could offer some protection against new virus variants, common colds, and help prepare for future pandemics. Developing a vaccine that provides protection against a number of different coronaviruses is a challenge because this family of viruses have many key differences, frequently mutate and generally induce incomplete pro
Drug Discovery Today
JULY 29, 2022
Registration is open for the UK’s largest trade show for the lab industry
Antidote
JULY 8, 2022
When you head to the pharmacy to pick up medicine, you likely aren’t thinking about all the steps it had to take to get into your hands — but did you know that on average, it takes about ten years for a new medication to make it to market ? This includes the six to seven years that the medicine will go through clinical trial phases, plus a few others that we’ll discuss below.
Drug Channels
JULY 12, 2022
Despite what you may have heard, pharmacy participation in the 340B Drug Pricing Program continues to thrive. Drug Channels Institute’s latest analysis reveals that an astonishing 32,000 pharmacy locations —more than half of the entire U.S. pharmacy industry—now act as contract pharmacies for the hospitals and other healthcare providers that participate in the 340B program.
Drug Patent Watch
JULY 1, 2022
Annual Drug Patent Expirations for ARMONAIR+DIGIHALER Armonair Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are twenty…. The post New patent for Teva Pharm drug ARMONAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Broad Institute
JULY 29, 2022
Group tour information By Maria Nemchuk July 29, 2022 Breadcrumb Home Group tour information Welcome Exhibits Plan your visit Book a group tour The Broad Discovery Center offers guided tours to visitors Monday - Wednesday at 11:00 AM, unless otherwise posted. Visitors should gather at the S-shaped sofa in the lobby. Reservations are not required for small groups, but are available to visitors interested in a short, guided experience.
Drug Discovery World
JULY 27, 2022
Biotechnology company Recursion has been granted an Orphan Drug Designation for its potential treatment of the rare disease familial adenomatous polyposis (FAP). . FAP is a rare tumour syndrome in which hundreds or thousands of precancerous colorectal polyps grow in the body. As it stands there are no approved therapies for the disease. . Recursion’s therapy REC-4881 is an orally bioavailable non-ATP-competitive allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce p
The Connected Lab
JULY 29, 2022
Biobanks play a crucial role in effectively managing and storing critical scientific data: biospecimens. For pharma and biotech companies, diagnostic laboratories, and contract research organizations, specimen integrity is critical to ensure robust and reproducible results. Thermo Scientific™ SampleManager LIMS™ software’s Biorepository Solution is an implementation and validation accelerator which uses industry-standard features, expertise and experience to expedite return on investment and red
Antidote
JULY 27, 2022
Kidney diseases are one of the top causes of death in the United States , and worldwide, they impact nearly 10% of the population each year. Because chronic kidney disease typically has no cure, it is vital that medical research takes place to find new and more effective treatments for those who have been diagnosed.
Drug Channels
JULY 6, 2022
The boom in copay accumulators and maximizers has radically shifted payers’ views on manufacturers’ copay support programs for specialty drugs. Below, I review a new survey of commercial plan sponsors and contrast the findings to a comparable survey from 2018. As you will see, plan sponsors now perceive manufacturers’ patient assistance programs primarily as a source of funding for their own plans.
Drug Patent Watch
JULY 1, 2022
Annual Drug Patent Expirations for PROAIR+RESPICLICK Proair Respiclick is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from two suppliers. There are…. The post New patent for Teva Branded drug PROAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
246 
Let's personalize your content